Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders... Show more
A.I.dvisor tells us that CELU and TELO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and TELO's prices will move in lockstep.
| Ticker / NAME | Correlation To CELU | 1D Price Change % | ||
|---|---|---|---|---|
| CELU | 100% | -1.02% | ||
| TELO - CELU | 28% Poorly correlated | -3.85% | ||
| NVCT - CELU | 27% Poorly correlated | -4.50% | ||
| PRAX - CELU | 27% Poorly correlated | +1.53% | ||
| RNAC - CELU | 26% Poorly correlated | +6.40% | ||
| SEER - CELU | 26% Poorly correlated | -1.73% | ||
More | ||||
a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
Be on the lookout for a price bounce soon.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CELU's RSI Indicator exited the oversold zone, 35 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The 50-day moving average for CELU moved above the 200-day moving average on October 01, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in 213 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CELU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CELU as a result. In 89 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CELU turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 47 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CELU moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CELU crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CELU entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.274) is normal, around the industry mean (2.904). P/E Ratio (-0.243) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (1.244) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CELU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.